Literature DB >> 12447696

Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity.

Claudia Miranda1, Giuseppe Zanotti, Sonia Pagliardini, Carola Ponzetto, Marco A Pierotti, Angela Greco.   

Abstract

Activation of tyrosine kinase receptors is associated with human tumors. Tumorigenic versions of several RTKs, such as Ret, Kit and Met carry activating mutations at highly conserved residues of the tyrosine kinase domain. We have investigated the effect of some of these mutations on the NTRK1/NGF receptor, for which no naturally occurring activating point mutations have been so far detected. We introduced the following mutations in NTRK1 tyrosine kinase domain: (i) D668N equivalent to Met D1246N associated to HPRC; (ii) D668V modelled on Kit D816V found in mastocytosis; (iii) M688T corresponding to Ret M918T associated to the cancer syndrome MEN2B. The Met-like mutation rendered the NTRK1 receptor more responsive to ligand, as observed for the corresponding mutation in Met. On the contrary the Kit-like D668V resulted as neutral mutation. Surprisingly, the MEN2B-like M688T completely abrogated NTRK1 receptor activity, resulting as a loss of function mutation. Our results show that the mutations tested, although involving conserved amino acids in highly homologous regions, exert distinct effects in different receptors, and suggest a very peculiar auto-inhibitory mechanism for NTRK1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447696     DOI: 10.1038/sj.onc.1206052

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  A short in-frame deletion in NTRK1 tyrosine kinase domain caused by a novel splice site mutation in a patient with congenital insensitivity to pain with anhidrosis.

Authors:  Esther Sarasola; Jose A Rodríguez; Elisa Garrote; Javier Arístegui; Maria J García-Barcina
Journal:  BMC Med Genet       Date:  2011-06-27       Impact factor: 2.103

2.  MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping.

Authors:  Jonathan M Tsai; Aaron N Hata; Jochen K Lennerz
Journal:  Oncologist       Date:  2021-08-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.